Breaking News Instant updates and real-time market news.

TEVA

Teva

$42.12

0.33 (0.79%)

09:12
10/18/16
10/18
09:12
10/18/16
09:12

Teva reports receipt of FDA warning letter related to plant inspection

In a regulatory filing, Teva Pharmaceutical disclosed that the company received a Warning Letter from the U.S. Food and Drug Administration connected with an FDA current Good Manufacturing Practices inspection of the company's Godollo manufacturing facility, which was conducted January 21, 2016 through January 29, 2016. The letter cites deficiencies in manufacturing operations and laboratory controls, and in the company's data integrity program. "Teva has undertaken corrective actions to address both the specific concerns raised by investigators as well as the underlying causes of those concerns. Communication with the FDA is ongoing. Teva will respond to the Warning Letter on November 4, 2016," the company stated.

  • 06

    Nov

  • 15

    Nov

TEVA Teva
$42.12

0.33 (0.79%)

10/06/16
WELS
10/06/16
NO CHANGE
WELS
Wells calls Teva partnership with Celltrion 'good news'
Wells Fargo analyst David Maris views Teva Pharmaceutical's partnership to commercialize two of Celltrion's monoclonal antibody biosimilar candidates as "good news." Teva is now a "little more firmly in the biosimilar game," Maris tells investors in a research note. He likes that the initial cash outflow is small and the partner. Maris has an Outperform rating on Teva.
10/07/16
LEER
10/07/16
NO CHANGE
Target $57
LEER
Outperform
Teva price target lowered to $57 from $61 at Leerink
Leerink analyst Jason Gerberry lowered his price target for Teva to $57 from $61 and trimmed his estimates to reflect near-term headwinds and a more conservative Copaxone outlook. The analyst continues to view a generic Copaxone launch in late the second half of 2017 as a risk. Nonetheless, Gerberry reiterates an Outperform rating on the stock as he views shares as attractively valued despite near-term EPS concerns and believes investor attention will eventually pivot to Teva's attractive late stage pipeline.
10/11/16
LEHM
10/11/16
UPGRADE
Target $19
LEHM
Overweight
Momenta upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Douglas Tsao upgraded Momenta Pharmaceuticals to Overweight after attending the consolidated Copaxone 40mg trial. The analyst sees low risk of Momenta being blocked from the 40mg opportunity past 2018 and views the stock's risk/reward as "compelling" at current levels. Tsao believes there is a "good likelihood" that Sandoz, Momenta's partner, launches Copaxone 40mg at-risk as soon as February 2017 upon FDA approval when the 30-month stay expires. The analyst raised his price target for Momenta shares to $19 from $13.
10/12/16
LEER
10/12/16
NO CHANGE
Target $70
LEER
Outperform
Neurocrine recent selloff a buying opportunity, says Leerink
Leerink analyst Paul Matteis views the 18% pullback in shares of Neurocrine Biosciences (NBIX) over the past few weeks as a buying opportunity. The analyst finds the catalyst for the selloff "difficult to pinpoint," but notes he's been receiving questions from investors on the size of the market opportunity for vesicular monoamine transporters in Tardive Dyskinesia. A doctor survey suggests a target market of 300,000 TD patients for Neurocrine's and Teva's VMAT2 inhibitors, which is enough to offer a "significant revenue opportunity" for both drugs, Matteis tells investors in a research note. Further, the analyst believes the upcoming Phase II data in Tourette's Syndrome, which he sees as having a high probability of success, offers a "nice catalyst for investors" into Q1 of next year. Matteis reiterates an Outperform rating on Neurocrine with a $70 price target.

TODAY'S FREE FLY STORIES

WDC

Western Digital

$85.71

1.1 (1.30%)

08:14
04/28/17
04/28
08:14
04/28/17
08:14
Downgrade
Western Digital rating change  »

Western Digital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$918.38

9.09 (1.00%)

08:13
04/28/17
04/28
08:13
04/28/17
08:13
Recommendations
Amazon.com analyst commentary  »

Amazon.com price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    May

  • 16

    May

  • 23

    May

LH

LabCorp

$139.68

0.99 (0.71%)

08:13
04/28/17
04/28
08:13
04/28/17
08:13
Hot Stocks
LabCorp to exclusively offer M3 Checklist for mental illness »

LabCorp and M-3…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    May

ATTO

Atento

$8.85

-0.1 (-1.12%)

08:13
04/28/17
04/28
08:13
04/28/17
08:13
Earnings
Atento announces prepayment of $27M Brazilian debentures »

Atento made a $26.7M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

  • 11

    May

08:12
04/28/17
04/28
08:12
04/28/17
08:12
Conference/Events
Cowen analysts hold an analyst/industry conference call »

Analysts provide an…

TER

Teradyne

$36.35

2.58 (7.64%)

08:12
04/28/17
04/28
08:12
04/28/17
08:12
Recommendations
Teradyne analyst commentary  »

Teradyne price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 03

    May

  • 04

    May

  • 21

    Jun

EXPE

Expedia

$136.20

0.45 (0.33%)

08:12
04/28/17
04/28
08:12
04/28/17
08:12
Recommendations
Expedia analyst commentary  »

Expedia price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    May

  • 16

    May

LLL

L3 Technologies

$173.94

2.18 (1.27%)

08:12
04/28/17
04/28
08:12
04/28/17
08:12
Recommendations
L3 Technologies analyst commentary  »

L3 Technologies price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZBH

Zimmer Biomet

$118.10

-7.22 (-5.76%)

, SYK

Stryker

$135.37

-0.82 (-0.60%)

08:11
04/28/17
04/28
08:11
04/28/17
08:11
Downgrade
Zimmer Biomet, Stryker rating change  »

Zimmer Biomet downgraded…

ZBH

Zimmer Biomet

$118.10

-7.22 (-5.76%)

SYK

Stryker

$135.37

-0.82 (-0.60%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 03

    May

  • 04

    May

PTEN

Patterson-UTI

$21.93

-1.07 (-4.65%)

08:11
04/28/17
04/28
08:11
04/28/17
08:11
Recommendations
Patterson-UTI analyst commentary  »

Patterson-UTI weakness a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

MGA

Magna

$41.40

0.56 (1.37%)

08:11
04/28/17
04/28
08:11
04/28/17
08:11
Hot Stocks
Magna enters joint venture with Chinese seating supplier »

Magna has entered into a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    May

  • 11

    May

XOM

Exxon Mobil

$81.26

-0.14 (-0.17%)

08:11
04/28/17
04/28
08:11
04/28/17
08:11
Hot Stocks
Exxon Mobil says Q1 Chemical earnings impacted primarily by lower margins »

Exxon Mobil reports Q1…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

RWLK

ReWalk Robotics

$1.45

-0.2 (-12.12%)

08:10
04/28/17
04/28
08:10
04/28/17
08:10
Hot Stocks
ReWalk Robotics names Jodi Gricci as Chief Commercial Officer »

ReWalk Robotics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    May

HON

Honeywell

$129.88

-0.22 (-0.17%)

08:10
04/28/17
04/28
08:10
04/28/17
08:10
Periodicals
Honeywell talks with Third Point still friendly, CNBC's Faber says »

Talks between Honeywell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

FSS

Federal Signal

$15.38

0.98 (6.81%)

08:10
04/28/17
04/28
08:10
04/28/17
08:10
Hot Stocks
Federal Signal awarded $128K of legal costs in hearing loss litigation »

Federal Signal announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVM

CEL-SCI

$0.10

-0.0099 (-9.00%)

08:09
04/28/17
04/28
08:09
04/28/17
08:09
Hot Stocks
CEL-SCI says European Patent office to grant new Multikine patent »

CEL-SCI Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SYF

Synchrony

$33.05

-0.18 (-0.54%)

08:09
04/28/17
04/28
08:09
04/28/17
08:09
Technical Analysis
Synchrony drops sharply after earnings miss consensus »

The stock was last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 18

    May

  • 31

    May

MSFT

Microsoft

$68.27

0.44 (0.65%)

08:09
04/28/17
04/28
08:09
04/28/17
08:09
Recommendations
Microsoft analyst commentary  »

Microsoft commercial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 09

    May

RCL

Royal Caribbean

$100.50

0.03 (0.03%)

08:08
04/28/17
04/28
08:08
04/28/17
08:08
Hot Stocks
Royal Caribbean sees FY17 CapEx $0.6B »

Based upon current ship…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

ACBI

Atlantic Capital

08:07
04/28/17
04/28
08:07
04/28/17
08:07
Earnings
Atlantic Capital reports Q1 EPS 13c, consensus 14c »

Taxable equivalent net…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 18

    May

RCL

Royal Caribbean

$100.50

0.03 (0.03%)

08:07
04/28/17
04/28
08:07
04/28/17
08:07
Earnings
Royal Caribbean sees Q2 adjusted EPS $1.60-$1.65, consensus $1.44 »

Constant-Currency Net…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

XOM

Exxon Mobil

$81.26

-0.14 (-0.17%)

08:07
04/28/17
04/28
08:07
04/28/17
08:07
Hot Stocks
Exxon Mobil reports Q1 capital and exploration expenditures down 19% »

Capital and exploration…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

MXWL

Maxwell

$6.24

-0.03 (-0.48%)

08:06
04/28/17
04/28
08:06
04/28/17
08:06
Earnings
Maxwell sees Nesscap Energy acquisition immediately accretive to non-GAAP EPS »

Acquisition is expected…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

  • 13

    Jul

RTN

Raytheon

$156.26

0.99 (0.64%)

08:06
04/28/17
04/28
08:06
04/28/17
08:06
Recommendations
Raytheon analyst commentary  »

Raytheon price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

RCL

Royal Caribbean

$100.50

0.03 (0.03%)

08:05
04/28/17
04/28
08:05
04/28/17
08:05
Hot Stocks
Breaking Hot Stocks news story on Royal Caribbean »

Royal Caribbean announces…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.